Submitted by kBLASTER Team on
New test detects MRSA and SA, the leading causes of healthcare-associated infections worldwide
Roche (SIX: RO, ROG.VX; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas® MRSA/SA Test for the early, simultaneous detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (SA) directly from nasal specimens. The cobas® MRSA/SA Test detects both organisms from a single specimen, providing accurate and reliable results for effective prevention and control of MRSA/SA infections.
Go to kBLASTER to FDA 510(k) search for a primary predicate, multiple predicates or reference devices, and harness kBLASTER's uniquely effective result management features, so you can quickly build a successful 510(k) clearance strategy.